Cholesterol and Cholesterol-Lowering Medications in COVID-19—An Unresolved Matter

URN to cite this document:: urn:nbn:de:bvb:355-epub-593525
DOI to cite this document:: 10.5283/epub.59352

Grewal, Thomas ; Nguyen, Mai Khanh Linh ; Buechler, Christa

License: Creative Commons Attribution 4.0
PDF - Published Version
(1MB)

Date of publication of this fulltext: 09 Oct 2024 09:53

Alternative links to fulltext:DOI Publisher

Details

Preview

Export bibliographical data

Abstract

Infections with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) cause coronavirus disease 2019 (COVID-19), a disease with very heterogeneous symptoms. Dyslipidaemia is prevalent in at least 20% of Europeans, and dyslipidaemia before SARS-CoV-2 infection increases the risk for severe COVID-19 and mortality by 139%. Many reports described reduced serum cholesterol levels in ...